Keen Therapeutics was recently founded aiming to become the next generation biotech in China. The Company is led by a group of spirited chemical biologist, biophysicist, immunologist, computational chemist, and algorithm engineer.Enabled by first-principle-based computational methods, the Company focuses on challenging targets/pathways to provide innovative cancer therapies. Through collaboration with niche CROs that are more focused and efficient, the Company tries to minimize the time and cost for pre-clinical discovery.The Company has made dedicated efforts and some progress in the area of cancer metabolism including ferroptosis. It is expected to nominate the first pre-clinical candidate by the end of 2022.